Patents by Inventor Chenmin TIAN

Chenmin TIAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-SOST Antibody Pharmaceutical Composition and Use Thereof
    Publication number: 20250011411
    Abstract: The present invention relates to an anti-SOST antibody pharmaceutical composition and a use thereof. In particular, the present invention relates to a pharmaceutical composition comprising an anti-SOST antibody and an antioxidant, and a use thereof for treating SOST-related diseases or disorders.
    Type: Application
    Filed: November 30, 2022
    Publication date: January 9, 2025
    Inventors: Shuang Shan, Chenmin Tian
  • PHARMACEUTICAL COMPOSITION COMPRISING ANTI-PVRIG/TIGIT BISPECIFIC ANTIBODY
    Publication number: 20240376207
    Abstract: A pharmaceutical composition comprising an anti-PVRIG/TIGIT bispecific antibody.
    Type: Application
    Filed: September 15, 2022
    Publication date: November 14, 2024
    Inventors: Jianjian Yang, Chenmin Tian
  • PHARMACEUTICAL COMPOSITION CONTAINING ANTI-TROP2 ANTIBODY DRUG CONJUGATE AND ITS APPLICATION
    Publication number: 20240325564
    Abstract: The disclosure relates to a pharmaceutical composition containing an anti-TROP2 antibody drug conjugate and its application. Specifically, the disclosure relates to a pharmaceutical composition comprising an antibody drug conjugate in a buffer. The pharmaceutical composition has good stability.
    Type: Application
    Filed: July 21, 2022
    Publication date: October 3, 2024
    Inventors: Xiyele MO, Chenmin TIAN, Xun LIU
  • TGF-beta RECEPTOR FUSION PROTEIN PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20220017601
    Abstract: Disclosed in the present disclosure are a TGF-? receptor fusion protein pharmaceutical composition and a use thereof. Specifically, the pharmaceutical composition comprises a TGF-? receptor fusion protein in a sodium citrate buffer, and the TGF-? receptor fusion protein comprises a PD-L1 antibody targeting portion and a TGF-?RII extracellular region. In addition, the pharmaceutical composition may also comprise a sugar and a non-ionic surfactant.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 20, 2022
    Inventors: Chenmin TIAN, Hao LI, Xun LIU
  • ANTI-TIM3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
    Publication number: 20210261663
    Abstract: Disclosed in the present application are a TIM3 antibody pharmaceutical composition and use thereof. In particular, the pharmaceutical composition comprises a TIM3 antibody or antigen-binding fragment thereof in a buffer. In addition, the pharmaceutical composition further comprises a saccharide and a nonionic surfactant. The pharmaceutical composition of the present invention has good stability.
    Type: Application
    Filed: August 27, 2019
    Publication date: August 26, 2021
    Inventors: Chenmin TIAN, Hao LI, Xun LIU, Zhuoxiao CAO
  • PHARMACEUTICAL COMPOSITION COMPRISING PCSK-9 ANTIBODY AND USE THEREOF
    Publication number: 20200223941
    Abstract: Provided is a pharmaceutical composition comprising a PCSK9 antibody or an antigen-binding fragment thereof in a histidine buffer. In addition, the pharmaceutical composition may also comprise saccharides and nonionic surfactants.
    Type: Application
    Filed: June 29, 2018
    Publication date: July 16, 2020
    Inventors: Chenmin TIAN, Hao LI, Xun LIU